Polynovo
PolyNovo specializes in developing and commercializing advanced medical devices using its proprietary NovoSorb technology. The company focuses on treating burns, surgical wounds, and providing solutions for Negative Pressure Wound Therapy, positioning itself as a leader in innovative healthcare solutions.
Short position
Polynovo (ASX:PNV) has 7.06% of its shares on issue reported as short positions as of 5 Oct 2026, or about 48,746,700 shares. Over the past 30 days that figure has fallen 0.90 percentage points, and over 90 days it has fallen 1.54 percentage points. Its highest recorded short interest was 14.61% in May 2026. PNV is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Polynovo (PNV) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $143.7Mvs $127.2M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- $7.3Mvs $13.2M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- $0.011vs $0.019 (FY25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- +12.9%FY
- EPS YoY
- −44.4%FY
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- 89.4%
- Operating margin
- 7.3%
- Net margin
- 5.1%
- FCF margin
- 6.5%
- ROE
- 8.4%
- ROA
- 5.7%
- FCF conversion
- 1.27×
- Net cash (excl. leases)
- $31.8M
- Net debt / EBITDA
- −3.0×
- Current ratio
- 3.0×
- Interest cover
- 42.5×
- Cash dividends paid / net profit
- n/a
- Market cap
- $645.9M
- P/E
- 89.0×
- P/B
- 7.1×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $143.7M | $127.2M | $103.2M | $65.2M |
| Gross profit | $128.5M | $122.0M | $97.7M | $60.8M |
| Operating income | $10.5M | $4.5M | $1.2M | −$6.2M |
| EBITDA | $10.8M | $10.5M | $4.0M | −$2.7M |
| EBIT | $8.1M | $7.8M | $1.9M | −$4.7M |
| Interest expense | $246.0K | $236.0K | $141.0K | $186.1K |
| Pretax income | $7.8M | $7.5M | $1.7M | −$4.9M |
| Tax | $477.0K | −$5.7M | −$3.5M | −$8.6K |
| NPAT | $7.3M | $13.2M | $5.3M | −$4.9M |
| Net interest income | −$786.0K | −$395.0K | $814.0K | $155.5K |
| EPS basic | $0.011 | $0.019 | $0.008 | −$0.007 |
| EPS diluted | $0.011 | $0.019 | $0.007 | −$0.007 |
| Shares | 690.8M | 690.8M | 690.2M | 690.2M |
Financial reports
The company's own filings, newest first
- PolyNovo FY26 Annual ReportAnnual Report15 Sep 2026via asx_announcements
- FY26 Full Year Results Investor PresentationFull Year Results26 Aug 2026via asx_announcements
- ASX Announcement - FY26 Full Year ResultsFull Year Results26 Aug 2026via asx_announcements
- FY26 Full Year Results and Appendix 4EAnnual Results26 Aug 2026via asx_announcements
- Webcast Recording - 1H26 Financial ResultsFinancial Report25 Feb 2026via asx_announcements
- Appendix 4D & H1 FY26 Financial StatementsHalf Year Results20 Feb 2026via asx_announcements
- 1H26 Results Presentation - Webcast LinkInvestor Presentation12 Feb 2026via asx_announcements
- Notice of Annual General MeetingAgm Address25 Sep 2025via asx_announcements
- FY25 Annual ReportAnnual Report8 Sep 2025via asx_announcements
- Webcast Recording - FY25 Results PresentationInvestor Presentation26 Aug 2025via asx_announcements
Showing 10 of 83 reports